UNITY Biotechnology's UBX1325 Shows Positive Results in DME

UNITY Biotechnology's UBX1325 Shows Positive Results in DME

April 25, 2023

Unity Biotechnology announced that the long-term follow-up of the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME) has yielded positive outcomes. The results indicate that a single injection of UBX1325 treatment resulted in a statistically significant improvement in vision, which lasted for the entire 48 weeks duration of the study.

The improvement was marked by a gain of +6.2 ETDRS letters from the baseline, showing a difference of +5.6 ETDRS letters when compared to patients who were treated with sham. Furthermore, the study demonstrated that patients who were treated with UBX1325 maintained stable CST, while there was worsening observed in patients treated with sham.

“This is a defining moment for the senolytic therapeutic hypothesis and is a pivotal moment for UNITY. Achieving sustained improvements in visual acuity and stabilization of retinal structure for almost 1 year after a single injection of UBX1325 is a remarkable result,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “UBX1325 is the only treatment candidate in clinical development that targets senescent cells to potentially modify the course of disease, and this therapeutic approach could redefine the standard of care in DME. Based on the strong emerging clinical profile of UBX1325, we are planning to move forward with our Phase 2b DME head-to-head study against aflibercept in the second half of 2023.”

The BEHOLD study enrolled patients who had been on anti-VEGF treatment for at least 6 months but continued to experience visual acuity deficits and residual retinal fluid. At the beginning of the study, the patients' average visual acuity was 61.4 ETDRS letters and had a CST of approximately 439.6 microns. Prior to study enrollment, the patients had received an average of 4 anti-VEGF injections in the 6 months leading up to the study, with the last injection occurring between 3-6 weeks before randomization. The study was completed by fifty patients and lasted for a 48-week extension period.

48-Week Phase 2 BEHOLD Data:

● UBX1325 demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or vasculitis

● Patients treated with UBX1325 had a mean change in BCVA of +6.2 ETDRS letters from baseline to 48 weeks (p=0.0037), representing a difference of +5.6 ETDRS letters compared to sham-treated patients (p=0.1198)

● Based on an analysis of the BCVA change from baseline to last observation before anti-VEGF rescue or end of study participation, UBX1325 showed a +7.6 ETDRS letter advantage over sham (p = 0.0007)

● Approximately 53% of UBX1325-treated patients went 48 weeks without requiring any anti-VEGF rescue treatment compared to only 22% of patients in the sham arm

● Patients treated with UBX1325 had a mean change in CST of -16.6 microns from baseline at 40 weeks, representing an improvement compared to sham of -56.3 microns (p = 0.0479); at 48 weeks, UBX1325 had a mean change of -13.7 microns representing an improvement of -37.9 microns compared to sham (p = NS, in part due to the low number of sham patients remaining rescue-free at 48 weeks).

“DME patients are challenging to treat, often requiring frequent injections to decrease retinal edema and improve or even maintain vision. In this study, UBX1325 achieved visual improvement with a single injection, and maintained this improvement in over 50% of patients for a year,” said Jeffrey S. Heier, M.D., Director of Retina Research at Ophthalmic Consultants of Boston. “UBX1325, with a novel mechanism of action, could be an important therapeutic option for patients with such a complex, multifactorial disease.”